Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha

Thomas Stauffer Larsen; Katrine F Iversen; Esben Hansen; Anders Bruun Mathiasen; Claus Werenberg Marcher; Mikael Brink Frederiksen; Herdis Larsen; Inge Helleberg; Caroline Hasselbalch Riley; Ole W Bjerrum; Dorthe Rønnov-Jessen; Michael Boe Møller; Karin de Stricker; Hanne Vestergaard; Hans Carl Hasselbalch

doi:10.1016/j.leukres.2013.06.012

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha

Thomas Stauffer Larsen, Katrine F Iversen, Esben Hansen, Anders Bruun Mathiasen, Claus Werenberg Marcher, Mikael Brink Frederiksen, Herdis Larsen, Inge Helleberg, Caroline Hasselbalch Riley, Ole W Bjerrum, Dorthe Rønnov-Jessen, Michael Boe Møller, Karin de Stricker, Hanne Vestergaard, Hans Carl Hasselbalch

Department of Clinical Medicine

66 Citations (Scopus)

Abstract

Within recent years data has accumulated demonstrating the efficacy of recombinant interferon alpha2 (rIFN-alpha2) in the treatment of chronic myeloproliferative neoplasms (MPNs). We report on clinical and molecular data in the largest cohort of JAK2 V617F mutant MPN Danish patients (n= 102) being treated long-term with rIFN-alpha2 (rIFN-alpha2a and rIFN-alpha2b in a non-clinical trial setting. The median follow-up was 42 months. We substantiate the capacity of rIFN-alpha2 to induce complete hematologic remissions (ET 95%, PV 68%) and molecular response. In total 76 patients (74.5%) had a decline in JAK2 V617F allele burden with a median reduction from baseline of 59% (95% c.i. 50-73%, range 3-99%). A decline in JAK2 V617F allele burden was recorded in both ET (median 24-10% (95% c.i.: 8-16%), and PV (median 59-35% (95% c.i.: 17-33%). Patients with the lowest pre-treatment JAK2 V617F allele burdens tend to achieve the most favourable responses on long term treatment with rIFN-alpha2. Eleven patients (10%) had deep molecular remissions with ≤2% JAK2 V617F mutant DNA. Finally, long term treatment with rIFN-alpha2 was associated with a very low thrombosis rate. Our observations are supportive of the concept of early up-front treatment with rIFN-alpha2.

Original language	English
Journal	Leukemia Research
Volume	37
Issue number	9
Pages (from-to)	1041-1045
Number of pages	5
ISSN	0145-2126
DOIs	https://doi.org/10.1016/j.leukres.2013.06.012
Publication status	Published - Sept 2013

Access to Document

10.1016/j.leukres.2013.06.012

Cite this

Stauffer Larsen, T., Iversen, K. F., Hansen, E., Mathiasen, A. B., Marcher, C. W., Frederiksen, M. B., Larsen, H., Helleberg, I., Riley, C. H., Bjerrum, O. W., Rønnov-Jessen, D., Møller, M. B., de Stricker, K., Vestergaard, H., & Hasselbalch, H. C. (2013). Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leukemia Research, 37(9), 1041-1045. https://doi.org/10.1016/j.leukres.2013.06.012

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. / Stauffer Larsen, Thomas; Iversen, Katrine F; Hansen, Esben et al.

In: Leukemia Research, Vol. 37, No. 9, 09.2013, p. 1041-1045.

Research output: Contribution to journal › Journal article › Research › peer-review

Stauffer Larsen, T, Iversen, KF, Hansen, E, Mathiasen, AB, Marcher, CW, Frederiksen, MB, Larsen, H, Helleberg, I, Riley, CH, Bjerrum, OW, Rønnov-Jessen, D, Møller, MB, de Stricker, K, Vestergaard, H & Hasselbalch, HC 2013, 'Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha', Leukemia Research, vol. 37, no. 9, pp. 1041-1045. https://doi.org/10.1016/j.leukres.2013.06.012

@article{6f3d954ffd194205a7e831e1e73b3df8,

title = "Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha",

abstract = "Within recent years data has accumulated demonstrating the efficacy of recombinant interferon alpha2 (rIFN-alpha2) in the treatment of chronic myeloproliferative neoplasms (MPNs). We report on clinical and molecular data in the largest cohort of JAK2 V617F mutant MPN Danish patients (n= 102) being treated long-term with rIFN-alpha2 (rIFN-alpha2a and rIFN-alpha2b in a non-clinical trial setting. The median follow-up was 42 months. We substantiate the capacity of rIFN-alpha2 to induce complete hematologic remissions (ET 95%, PV 68%) and molecular response. In total 76 patients (74.5%) had a decline in JAK2 V617F allele burden with a median reduction from baseline of 59% (95% c.i. 50-73%, range 3-99%). A decline in JAK2 V617F allele burden was recorded in both ET (median 24-10% (95% c.i.: 8-16%), and PV (median 59-35% (95% c.i.: 17-33%). Patients with the lowest pre-treatment JAK2 V617F allele burdens tend to achieve the most favourable responses on long term treatment with rIFN-alpha2. Eleven patients (10%) had deep molecular remissions with ≤2% JAK2 V617F mutant DNA. Finally, long term treatment with rIFN-alpha2 was associated with a very low thrombosis rate. Our observations are supportive of the concept of early up-front treatment with rIFN-alpha2.",

author = "{Stauffer Larsen}, Thomas and Iversen, {Katrine F} and Esben Hansen and Mathiasen, {Anders Bruun} and Marcher, {Claus Werenberg} and Frederiksen, {Mikael Brink} and Herdis Larsen and Inge Helleberg and Riley, {Caroline Hasselbalch} and Bjerrum, {Ole W} and Dorthe R{\o}nnov-Jessen and M{\o}ller, {Michael Boe} and {de Stricker}, Karin and Hanne Vestergaard and Hasselbalch, {Hans Carl}",

year = "2013",

month = sep,

doi = "10.1016/j.leukres.2013.06.012",

language = "English",

volume = "37",

pages = "1041--1045",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Pergamon Press",

number = "9",

}

TY - JOUR

T1 - Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha

AU - Stauffer Larsen, Thomas

AU - Iversen, Katrine F

AU - Hansen, Esben

AU - Mathiasen, Anders Bruun

AU - Marcher, Claus Werenberg

AU - Frederiksen, Mikael Brink

AU - Larsen, Herdis

AU - Helleberg, Inge

AU - Riley, Caroline Hasselbalch

AU - Bjerrum, Ole W

AU - Rønnov-Jessen, Dorthe

AU - Møller, Michael Boe

AU - de Stricker, Karin

AU - Vestergaard, Hanne

AU - Hasselbalch, Hans Carl

PY - 2013/9

Y1 - 2013/9

N2 - Within recent years data has accumulated demonstrating the efficacy of recombinant interferon alpha2 (rIFN-alpha2) in the treatment of chronic myeloproliferative neoplasms (MPNs). We report on clinical and molecular data in the largest cohort of JAK2 V617F mutant MPN Danish patients (n= 102) being treated long-term with rIFN-alpha2 (rIFN-alpha2a and rIFN-alpha2b in a non-clinical trial setting. The median follow-up was 42 months. We substantiate the capacity of rIFN-alpha2 to induce complete hematologic remissions (ET 95%, PV 68%) and molecular response. In total 76 patients (74.5%) had a decline in JAK2 V617F allele burden with a median reduction from baseline of 59% (95% c.i. 50-73%, range 3-99%). A decline in JAK2 V617F allele burden was recorded in both ET (median 24-10% (95% c.i.: 8-16%), and PV (median 59-35% (95% c.i.: 17-33%). Patients with the lowest pre-treatment JAK2 V617F allele burdens tend to achieve the most favourable responses on long term treatment with rIFN-alpha2. Eleven patients (10%) had deep molecular remissions with ≤2% JAK2 V617F mutant DNA. Finally, long term treatment with rIFN-alpha2 was associated with a very low thrombosis rate. Our observations are supportive of the concept of early up-front treatment with rIFN-alpha2.

AB - Within recent years data has accumulated demonstrating the efficacy of recombinant interferon alpha2 (rIFN-alpha2) in the treatment of chronic myeloproliferative neoplasms (MPNs). We report on clinical and molecular data in the largest cohort of JAK2 V617F mutant MPN Danish patients (n= 102) being treated long-term with rIFN-alpha2 (rIFN-alpha2a and rIFN-alpha2b in a non-clinical trial setting. The median follow-up was 42 months. We substantiate the capacity of rIFN-alpha2 to induce complete hematologic remissions (ET 95%, PV 68%) and molecular response. In total 76 patients (74.5%) had a decline in JAK2 V617F allele burden with a median reduction from baseline of 59% (95% c.i. 50-73%, range 3-99%). A decline in JAK2 V617F allele burden was recorded in both ET (median 24-10% (95% c.i.: 8-16%), and PV (median 59-35% (95% c.i.: 17-33%). Patients with the lowest pre-treatment JAK2 V617F allele burdens tend to achieve the most favourable responses on long term treatment with rIFN-alpha2. Eleven patients (10%) had deep molecular remissions with ≤2% JAK2 V617F mutant DNA. Finally, long term treatment with rIFN-alpha2 was associated with a very low thrombosis rate. Our observations are supportive of the concept of early up-front treatment with rIFN-alpha2.

U2 - 10.1016/j.leukres.2013.06.012

DO - 10.1016/j.leukres.2013.06.012

M3 - Journal article

C2 - 23827351

SN - 0145-2126

VL - 37

SP - 1041

EP - 1045

JO - Leukemia Research

JF - Leukemia Research

IS - 9

ER -

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha

Abstract

Access to Document

Fingerprint

Cite this